|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date17 Jul 2017 |
CVL237 片治疗 PTEN 缺失的晚期实体瘤的单臂、开放、多中心、II 期临床研究
[Translation] Single-arm, open-label, multi-center, phase II clinical study of CVL237 tablets for the treatment of PTEN-deficient advanced solid tumors
1、主要研究目的:
评估 CVL237 片在 PTEN 缺失的晚期实体瘤患者中的初步有效性。
2、次要研究目的:
(1) 评估 CVL237 在 PTEN 缺失的晚期实体瘤患者中的安全性;
(2) 评估 CVL237 在 PTEN 缺失的晚期实体瘤患者中的药代动力学特征;
(3) 初步探索生物标记物与抗肿瘤活性的关系。
[Translation] 1. Main research purpose:
To evaluate the preliminary efficacy of CVL237 tablets in patients with PTEN-deficient advanced solid tumors.
2. Secondary research purpose:
(1) To evaluate the safety of CVL237 in patients with PTEN-deficient advanced solid tumors;
(2) evaluate the pharmacokinetic characteristics of CVL237 in patients with PTEN-deficient advanced solid tumors;
(3) Preliminarily explore the relationship between biomarkers and anti-tumor activity.
100 Clinical Results associated with Zhejiang Fukang Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Zhejiang Fukang Pharmaceutical Co., Ltd.
100 Deals associated with Zhejiang Fukang Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Zhejiang Fukang Pharmaceutical Co., Ltd.